Cho BS, et al. - For the first time, the impact of deferasirox after allogeneic hematopoietic stem cell transplantation (allo-HSCT) in acute myeloid leukemia (AML) was investigated. Analysis of 326 consecutive patients undergoing allo-HSCT in remission was done. Among 198 patients who were not receiving deferasirox, hyperferritinemia (≥1000 ng/mL) before and after allo-HSCT had a negative prognostic effect on survival mainly due to an increase in relapse. Deferasirox was administered to 128 patients (46%) of 276 patients with hyperferritinemia at 1 month after allo-HSCT. Deferasirox led to the improved survival and restoration of graft-vs-leukemia (GVL) effects of patients with AML. This study further suggests the detrimental effect of hyperferritinemia through after allo-HSCT.